Current stock page

Stock Analysis

Arbutus Biopharma Corp (ABUS) Stock Analysis

Arbutus Biopharma Corp (ABUS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

ABUS Stock Analysis Summary

Arbutus Biopharma Corp (ABUS) currently has an AIQ Score of 70/100, indicating a bullish setup. Value is the strongest factor at 92/100. Momentum is the weakest current factor at 51/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

ABUS at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$4.09
AIQ Score70/100
Overall ViewBullish
Technical Analysis ConsensusNeutral
Market Cap$812.59M
P/E Ratio (TTM)3.62
Forward P/E—
EPS (Q3 FY2026)$0.30
Revenue (Q3 FY2026)$299K
Dividend Yield (TTM)0.00%
Beta1.19
Volume3.31M
52-week range$3.50-$5.45
RSI 1448.5
50-Day SMA$4.46
200-Day SMA$4.48
Analyst Price Target—
Next EarningsMar 4, 2027
As of Nov 13, 2026 · Market close

ABUSArbutus Biopharma Corp

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$4.09+$0.06 (+1.49%)

Latest quote

  • Momentum
    51
  • Value
    92
  • Quality
    82
  • Risk resilience
    62
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

ABUS Stock Analysis Summary

Arbutus Biopharma Corp (ABUS) currently has an AIQ Score of 70/100, indicating a bullish setup. Value is the strongest factor at 92/100. Momentum is the weakest current factor at 51/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, ABUS has AIQ Score of 70/100 with Value base of 92/100 and fading Momentum at 51/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Value (92/100) leads while Momentum (51/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 1.49% stock move · ABUS classified in Biotechnology.

Current Evidence

BullishABUS is in a bullish AIQ regime; Value is the strongest visible factor at 92/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is ABUS Bullish or Bearish Right Now?

ABUS currently has a bullish overall setup. Value is the strongest factor at 92/100, while Momentum is weakest at 51/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 82/100.
Bear Case
  • - Price is -8.72% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (20 vs 18).

Current Consensus

ABUS's Technical Analysis Consensus is currently Neutral, with 18 buy, 8 neutral, and 20 sell votes. ABUS's 14-day RSI is 48.5, which places the stock in a neutral momentum range. ABUS's beta is 1.19, indicating market sensitivity broadly in line with the market.

Signal Confidence
Moderate agreement

What Changed in ABUS?

The largest recent change in ABUS is Value moving up by 8.0 points over the available 7-day comparison window. Value remains the strongest visible factor.

AIQ Score
+2.0
Momentum
-3.0
Quality
+5.0
Risk
+2.0

What Would Change the ABUS Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

ABUS Decision Framework

Public evidence layers, setup checks, and risk context for Arbutus Biopharma Corp.

Arbutus Biopharma Corp (ABUS) Stock Analysis

Arbutus Biopharma Corp has an AIQ Score of 70/100 in a Bullish regime. Value is strongest at 92/100. Beta is 1.19, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextABUS is in a Bullish AIQ regime with score 70/100.
Signal ConflictThe primary conflict is that value leads at 92/100 while momentum lags at 51/100.
Factor EvidenceMomentum 51/100 · Value 92/100 · Quality 82/100 · Risk 62/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Value is the strongest factor at 92/100.

TimingWait

Momentum is 51/100 and RSI (14) is 48.5.

Regime fitPass

ABUS is in a Bullish regime at 70/100.

Risk controlWait

Risk factor is 62/100 with beta 1.19 and annual volatility 45.89%.

ConflictWait

Current conflict: value leads at 92/100 while momentum lags at 51/100.

AIQ Score
70/100
Price
$4.09
Beta
1.19
RSI (14)
48.5

ABUS Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

ABUS Fundamentals

ABUS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$299K
Net income
$59.12M
Free cash flow
$239.81M
View full ABUS fundamental analysis

ABUS Technical Analysis

ABUS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Neutral
RSI 14
48.5
Price vs SMA-50
-8.31%
View full ABUS technical analysis

ABUS Stock Catalysts

Track ABUS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 4, 2027
Analyst target
—
News items
3
View ABUS earnings and stock catalysts

ABUS Dividend Analysis

ABUS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View ABUS dividend history and analysis

ABUS Financial Data

ABUS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$299K
EPS
$0.30
Periods
8
View ABUS financials

ABUS Risk Analysis

ABUS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.19
Risk score
62/100
1Y volatility
45.89%
View ABUS risk analysis

ABUS Stock News

ABUS stock news, market tone, recent headlines, and catalyst context.

News items
3
Updated
Nov 15, 2026
Sentiment
—
Read ABUS stock news

ABUS vs Biotechnology Peers

Current peer cohort: ABUS · ABVX · ADMA · AGIO · ALMS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
ABUS
Current stock
70/10092/10051/10062/100-0.0945.89%Current
ABVX
Abivax S.A.
35/100—34/10037/1000.2486.44%ABUS vs ABVX
ADMA
ADMA Biologics, Inc.
78/10080/10091/10056/100-0.0158.93%ABUS vs ADMA
AGIO
Agios Pharmaceuticals, Inc.
56/10052/10061/10047/1000.0779.96%ABUS vs AGIO
ALMS
Alumis Inc.
20/100—13/10020/1000.65137.60%ABUS vs ALMS
Pairwise Compare links: ABVX · ADMA · AGIO · ALMSABUS vs ABVXABUS vs ADMAABUS vs AGIOABUS vs ALMSCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a ABUS stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for ABUS: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
3.62
As of Nov 13, 2026
Revenue growth
-43.48%
Gross margin
99.99%
Current debt / equity
0
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$299K
Quarter net income
$59.12M
Quarter free cash flow
$239.81M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Mixed
RSI 14
48.5
MACD
-0.15

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
62/100
Beta
1.19
Annual volatility
45.89%
Max drawdown
-29.98%

ABUS Stock FAQ

What is ABUS stock price today?

Arbutus Biopharma Corp's current stock price is $4.09. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is ABUS bullish or bearish right now?

ABUS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is ABUS's market cap?

ABUS's market cap is $812.59M based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is ABUS's current P/E ratio?

ABUS's current P/E ratio is 3.62 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is ABUS's RSI?

ABUS's 14-day RSI is 48.5 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is ABUS above its 50-day and 200-day moving averages?

ABUS is -8.31% from its 50-day SMA and -8.72% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is ABUS's next earnings date?

ABUS's next earnings date is currently listed as Mar 4, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does ABUS pay a dividend?

ABUS's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.